Objective. To evaluate the five-year results of combined treatment of patients with large choroid melanoma.

Material and methods. Information from the Belarusian Cancer Registry and medical records of 60 patients with choroid melanoma cT2-3N0M0. For a comparative assessment of 5-year metastatic-free and overall survival a retrospective group of 88 patients who underwent enucleation was formed. Overall and metastatic-free survival was calculated with Kaplan-Meier method with a p log-rank significance assessment. The median follow-up was determined by the inverse Kaplan-Meier method.

Results. A positive result after combined treatment was achieved in 43 (71.7%) patients; continued growth — in
7 patients, relapse — in 7 patients. 17 (28.28%) enucleations were performed. Disease-free survival after combined treatment was 72.6%. Median overall and metastatic-free survival was not achieved in the two groups. With cT2N0M0 the overall 5-year survival rate after combined treatment was 94.9±3.5%, after enucleation — 67.6±10.1% (p=0.046). Cumulative 5-year metastatic-free survival after combined treatment was 81.7±6.2%, after enucleation — 79.2±9.3% (p=0.855). With cT3N0M0 the 5-year survival rate after combined treatment was 71.4±9.9%, after enucleation — 68.2±6.2% (p=0.54).

Сonclusion. Combined treatment of large choroid melanomas, including simultaneous TTT, PDT and BT with 106Ru + 106Rh isotopes, allows to destruct of T2-3N0M0 tumors with a 5-year level of preservation of the eyeball
in 71.7% of cases, residual vision acuty in 68,3% of patients, with an overall 5-year survival rate of 94.9±3.5% within T2N0M0 tumors.